Related Experiment Videos
Editorial: safety and tolerability of rifaximin for IBS - more information is required; authors' reply
1Division of Gastroenterology, University of Michigan School of Medicine, Ann Arbor, MI, USA. pschoenf@umich.edu.
Alimentary Pharmacology & Therapeutics
|June 20, 2014
Abstract
No abstract available in PubMed .
Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
Repeat Rifaximin for Irritable Bowel Syndrome: No Clinically Significant Changes in Stool Microbial Antibiotic Sensitivity.
Digestive diseases and sciences·2017
Do Jackhammer contractions lead to achalasia? A longitudinal study.
Neurogastroenterology and motility·2016
Can three-dimensional high-resolution anorectal manometry detect anal sphincter defects in patients with faecal incontinence?
Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland·2016
Review article: potential mechanisms of action of rifaximin in the management of irritable bowel syndrome with diarrhoea.
Alimentary pharmacology & therapeutics·2015
Review article: inhibition of methanogenic archaea by statins as a targeted management strategy for constipation and related disorders.
Alimentary pharmacology & therapeutics·2015
Status of Competency-Based Medical Education in Endoscopy Training: A Nationwide Survey of US ACGME-Accredited Gastroenterology Training Programs.
The American journal of gastroenterology·2015
Meta-Analysis: The Placebo Response in Modern Treatments for Cholestatic Pruritus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Alimentary pharmacology & therapeutics·2026
Medication Use and Risk of Microscopic Colitis: A Propensity-Matched Analysis of US Adults ≥ 50 Years (2014-2024).
Alimentary pharmacology & therapeutics·2026
Carriage of the Laboratory of Genetics and Physiology Protein 2 Q425R Variant Reduces Liver Disease Severity in European Patients With Chronic Hepatitis Delta.
Alimentary pharmacology & therapeutics·2026
Towards Precision Medicine in Inflammatory Bowel Diseases: Pharmacogenetic Predictors of Ustekinumab Effectiveness and Persistence.
Pharmaceuticals (Basel, Switzerland)·2026
Targeting HMGB1 for Renal Ischemia and Reperfusion Injury: Mechanisms and Therapeutic Strategies.
Pharmaceuticals (Basel, Switzerland)·2026